Literature DB >> 23288359

Sibling rivalry: competition between MHC class II family members inhibits immunity.

Lisa K Denzin1, Peter Cresswell.   

Abstract

Peptide loading of major histocompatibility complex (MHC) class II molecules in the endosomes and lysosomes of antigen-presenting cells is catalyzed by human leukocyte antigen-DM (HLA-DM) and modulated by HLA-DO. In a structural study in this issue, Guce et al. show that HLA-DO is an MHC class II mimic and functions as a competitive and essentially irreversible inhibitor of HLA-DM activity, thereby inhibiting MHC class II antigen presentation.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23288359     DOI： 10.1038/nsmb.2484

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN： 1545-9985            Impact factor:   15.369


  25 in total

1.  Regulation of MHC class II antigen presentation by sorting of recycling HLA-DM/DO and class II within the multivesicular body.

Authors:  M van Lith; M van Ham; A Griekspoor; E Tjin; D Verwoerd; J Calafat; H Janssen; E Reits; L Pastoors; J Neefjes
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

2.  A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM.

Authors:  Francis Deshaies; Alexandre Brunet; Djibril A Diallo; Lisa K Denzin; Angela Samaan; Jacques Thibodeau
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-22       Impact factor: 11.205

Review 3.  Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.

Authors:  Robert Busch; Cornelia H Rinderknecht; Sujin Roh; Andrew W Lee; James J Harding; Timo Burster; Tara M C Hornell; Elizabeth D Mellins
Journal:  Immunol Rev       Date:  2005-10       Impact factor: 12.988

4.  Mediation by HLA-DM of dissociation of peptides from HLA-DR.

Authors:  V S Sloan; P Cameron; G Porter; M Gammon; M Amaya; E Mellins; D M Zaller
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962

5.  Crystal structure of mouse H2-M.

Authors:  D H Fremont; F Crawford; P Marrack; W A Hendrickson; J Kappler
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

6.  Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis.

Authors:  Taejin Yoon; Henriette Macmillan; Sarah E Mortimer; Wei Jiang; Cornelia H Rinderknecht; Lawrence J Stern; Elizabeth D Mellins
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

7.  HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport.

Authors:  M Liljedahl; T Kuwana; W P Fung-Leung; M R Jackson; P A Peterson; L Karlsson
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

8.  HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide.

Authors:  Anne-Kathrin Anders; Melissa J Call; Monika-Sarah E D Schulze; Kevin D Fowler; David A Schubert; Nilufer P Seth; Eric J Sundberg; Kai W Wucherpfennig
Journal:  Nat Immunol       Date:  2010-12-05       Impact factor: 25.606

9.  HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules.

Authors:  L K Denzin; C Hammond; P Cresswell
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

10.  HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism.

Authors:  Abigail I Guce; Sarah E Mortimer; Taejin Yoon; Corrie A Painter; Wei Jiang; Elizabeth D Mellins; Lawrence J Stern
Journal:  Nat Struct Mol Biol       Date:  2012-12-09       Impact factor: 15.369
View more
  11 in total

Review 1.  Mechanisms of peptide repertoire selection by HLA-DM.

Authors:  Wouter Pos; Dhruv K Sethi; Kai W Wucherpfennig
Journal:  Trends Immunol       Date:  2013-07-05       Impact factor: 16.687

2.  Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.

Authors:  Jason M God; Christine Cameron; Janette Figueroa; Shereen Amria; Azim Hossain; Bettina Kempkes; Georg W Bornkamm; Robert K Stuart; Janice S Blum; Azizul Haque
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

Review 3.  Determinants of immunodominance for CD4 T cells.

Authors:  AeRyon Kim; Scheherazade Sadegh-Nasseri
Journal:  Curr Opin Immunol       Date:  2015-01-08       Impact factor: 7.486

Review 4.  What to do with HLA-DO/H-2O two decades later?

Authors:  Robin Welsh; Nianbin Song; Scheherazade Sadegh-Nasseri
Journal:  Immunogenetics       Date:  2019-01-26       Impact factor: 2.846

Review 5.  HLA-DO and Its Role in MHC Class II Antigen Presentation.

Authors:  Yuri O Poluektov; Aeryon Kim; Scheherazade Sadegh-Nasseri
Journal:  Front Immunol       Date:  2013-08-29       Impact factor: 7.561

6.  Exogenous Thyropin from p41 Invariant Chain Diminishes Cysteine Protease Activity and Affects IL-12 Secretion during Maturation of Human Dendritic Cells.

Authors:  Tina Zavašnik-Bergant; Martina Bergant Marušič
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

Review 7.  Introduction: MHC/KIR and governance of specificity.

Authors:  Adrian Kelly; John Trowsdale
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 2.846

Review 8.  How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?

Authors:  Robin A Welsh; Nianbin Song; Scheherazade Sadegh-Nasseri
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 9.  MHC Class II Auto-Antigen Presentation is Unconventional.

Authors:  Scheherazade Sadegh-Nasseri; AeRyon Kim
Journal:  Front Immunol       Date:  2015-07-22       Impact factor: 7.561

Review 10.  A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells.

Authors:  Scheherazade Sadegh-Nasseri
Journal:  F1000Res       Date:  2016-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.